Conagra Brands's Next Earnings Report on Sep. 30 2026 Could Send the Stock Soaring. Here's Why.

Conagra is expected to report fiscal 2027 Q1 net sales of $2.59 billion, down nearly 2% year over year, and adjusted EPS of $0.28, down 28%. The company’s fundamentals remain under pressure: fiscal 2026 GAAP net loss was $1.9 billion, including more than $2.9 billion of non-cash impairments, while adjusted profit fell to $823 million from over $1.1 billion. A 50% dividend cut to just under $0.18 per share—the first reduction since 2006—underscores the financial strain, although a decisive earnings beat or strategic changes under new CEO John Brase could support the shares.

Analysis

CAG’s setup is less about a one-quarter EPS beat than whether management can demonstrate that volume erosion and trade-down pressure have bottomed without further promotional intensity. A small adjusted-EPS beat is likely low quality if it comes from timing, lower marketing, or temporary cost controls; the market needs evidence of stable household penetration, improving mix, and gross-margin protection. The dividend reset has removed a key shareholder base and raises the required proof threshold for a multiple recovery, particularly given the impairment-driven signal that legacy brand carrying values were too optimistic.

Near term, the asymmetry remains negative: another guide-down or evidence that savings are being reinvested into price promotions could drive a 10-15% move lower, versus perhaps 5-8% upside on an in-line-to-modest beat. The more relevant 1-3 month catalyst is the first full articulation of the new CEO’s portfolio, SKU rationalization, pricing, and capital-allocation plan. A credible strategy could support a rerating over 6-18 months, but only if organic sales stabilize and adjusted operating margin does not deteriorate; broad “healthier portfolio” rhetoric without measurable targets should be sold.

Competitive read-through favors scaled branded peers with stronger category exposure and balance sheets, including GIS, KHC and CPB, if CAG must increase promotions to defend shelf space. Private-label suppliers and retailers could gain negotiating leverage if branded frozen and snack demand weakens, while CAG’s reduced dividend flexibility limits its ability to offset weak fundamentals through capital returns. Consensus may be too focused on the low EPS bar: the important downside is a structurally lower FCF conversion rate if working capital, promotions, and reinvestment rise simultaneously.

Key Decisions for Investors

• Maintain an underweight/short bias in CAG into earnings; use a defined-risk put spread 1-2 months out rather than outright short exposure. Target a 10-15% downside on a guidance reset; exit if organic sales stabilize and management guides to flat-to-up adjusted operating margin.
• Pair trade: long GIS or CPB / short CAG over the next 1-3 months. The pair expresses relative category and execution quality while reducing broad packaged-food beta; reassess if CAG provides quantified portfolio actions with a credible 12-month margin bridge.
• Do not buy a post-earnings CAG dip solely on an EPS beat. Require confirmation that volume/mix is improving and that gross-margin gains are not funded by lower advertising or inventory liquidation before considering a 6-18 month turnaround long.
• Watch retailer scanner data and the next guidance update for promotional intensity, frozen-food velocities, and net-debt/EBITDA direction. A sustained deterioration in any two would increase conviction in the short; stable velocities plus margin protection would falsify the bearish thesis.